Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Bispecific antibodies for non-Hodgkin lymphoma

Martin Hutchings • 18 Jun 2020
EHA 2020
Non-Hodgkin Lymphoma Antibodies Epcoritamab Glofitamab

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, reflects on the use of bispecific antibodies in the treatment of non-Hodgkins lymphoma, including glofitamab and epcoritamab, both CD20xCD3 bispecific antibodies. Furthermore, Dr Hutchings elaborates on the implementation of bispecific antibodies in the treatment regime of non-Hodgkins lymphoma patients and its curative potential for highly refractory patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Martin Hutchings

The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
18:55
The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
Elizabeth Budde et al. • 28 Sep 2025
Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL
1:49
Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL
Martin Hutchings • 7 Dec 2024
The BP41072 trial: glofitamab plus englumafusp alfa in patients with R/R B-NHL
3:17
The BP41072 trial: glofitamab plus englumafusp alfa in patients with R/R B-NHL
Martin Hutchings • 7 Dec 2024
Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R/R LBCL, including HGBCL
2:02
Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R/R LBCL, including HGBCL
Martin Hutchings • 7 Dec 2024

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals